Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Tesla Raises Cybertruck Prices by $5,000 in US 
Trump Buys SpaceX Shares After Record IPO 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Add as a preferred source on Google
NEW YORK, May 02, 2018 -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced that management will present a corporate overview at Deutsche Bank’s 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 10:40 a.m. ET.
A live audio webcast of the presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the company's website for two weeks following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome in 2017 and completed a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of epileptic encephalopathies and in 2017 initiated a Phase 1b/2a trial of OV935.
For more information on Ovid, please visit http://www.ovidrx.com/.
Contacts:
Ovid Therapeutics Inc.
Lora Pike
Senior Director, Investor Relations & Public Relations
[email protected]
OR
Investors:
Burns McClellan
Steve Klass, 212-213-0006
[email protected]
